GPT and Hyperbilirubinemia: The grade 3–4 adverse events (AEs) more common in the HAIC-LEN-PD1 group included alanine aminotransferase (ALT) elevation (20.4% vs. 8.2%, p = 0.039), neutropenia (11.7% vs.1.6%, p = 0.014), thrombocytopenia (16.5% vs.3.3%, p = 0.011), vomiting (9.7% vs.1.6%, p = 0.046), and hyperbilirubinemia (17.5% vs. 4.9%, p = 0.020).